332 related articles for article (PubMed ID: 26658418)
21. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
22. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
23. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.
Jouni H; Aubry MC; Lacy MQ; Vincent Rajkumar S; Kumar SK; Frye RL; Herrmann J
Am J Hematol; 2017 Feb; 92(2):220-221. PubMed ID: 27859518
[No Abstract] [Full Text] [Related]
24. Emerging antibodies for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
[TBL] [Abstract][Full Text] [Related]
25. CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
Wong SW; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):635-45. PubMed ID: 26443328
[TBL] [Abstract][Full Text] [Related]
26. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
[TBL] [Abstract][Full Text] [Related]
27. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.
Hofmeister CC; Lonial S
J Clin Oncol; 2016 Dec; 34(36):4421-4430. PubMed ID: 27998219
[TBL] [Abstract][Full Text] [Related]
28. Elotuzumab May Slow Multiple Myeloma.
Cancer Discov; 2015 Jul; 5(7):OF10. PubMed ID: 25998398
[No Abstract] [Full Text] [Related]
29. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
Jelinek T; Hajek R
Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
[TBL] [Abstract][Full Text] [Related]
30. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
[TBL] [Abstract][Full Text] [Related]
31. Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma.
Dimopoulos MA; Kastritis E; Terpos E
JAMA Oncol; 2016 Oct; 2(10):1261-1262. PubMed ID: 27585121
[No Abstract] [Full Text] [Related]
32. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma yields to CD38 inhibitors.
Cancer Discov; 2015 Mar; 5(3):OF5. PubMed ID: 25596281
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
35. New investigational drugs with single-agent activity in multiple myeloma.
Rajan AM; Kumar S
Blood Cancer J; 2016 Jul; 6(7):e451. PubMed ID: 27471867
[TBL] [Abstract][Full Text] [Related]
36. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
[TBL] [Abstract][Full Text] [Related]
37. Ixazomib and lenalidomide maintenance therapy in multiple myeloma.
Parrondo RD; Alegria V; Roy V; Sher T; Chanan-Khan AA; Ailawadhi S
Ann Hematol; 2021 Mar; 100(3):851-853. PubMed ID: 33161454
[No Abstract] [Full Text] [Related]
38. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Abramson HN
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544512
[TBL] [Abstract][Full Text] [Related]
39. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab for the Treatment of Multiple Myeloma.
Plesner T; Krejcik J
Front Immunol; 2018; 9():1228. PubMed ID: 29915586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
